advertisement
Abstract #5433 Published in IGR 1-2
A randomized study of dorzolamide in the prevention of elevated intraocular pressure after anterior segment laser surgery
Hartenbaum D; Wilson H; Maloney S; Vacarelli L; Orillac R; Sharpe E; Dorzolamide Laser Study GroupJournal of Glaucoma 1999; 8: 273-275
PURPOSE: To evaluate the efficacy of 2% dorzolamide hydrochloride ophthalmic solution in preventing spikes in intraocular pressure (IOP) after anterior segment laser surgery. METHODS: This 24-hour, placebo-controlled, randomized, double-masked, multi-center evaluation was conducted to determine the efficacy of dorzolamide hydrochloride 2% in controlling IOP after neodymium:yttrium-aluminum-garnet (Nd:YAG) laser capsulotomy, argon laser trabeculoplasty, or laser iridotomy. The 122 patients enrolled were assigned in random fashion to receive dorzolamide or placebo 1 hour before and immediately after the procedure; IOP was measured 1, 2, 3, 4, and 24 hours after the procedure. RESULTS: Of 61 patients receiving dorzolamide, only one (1.7%) had a spike in IOP of 10 mmHg or more, compared with 9 (14.8%) of the 61 patients receiving placebo. Mean IOP among patients receiving dorzolamide was significantly reduced both from baseline and compared with that among patients receiving placebo from 1 to 4 hours after administration. Only 5 (8%) of the 61 patients receiving dorzolamide experienced at least one adverse event, compared with 15 (25%) of the 61 patients receiving placebo. CONCLUSION: Dorzolamide was effective in preventing spikes in IOP after anterior segment laser surgery. Dorzolamide was generally well tolerated after short-term use.
D. Hartenbaum, 1600 Whitehouse Road, Maple Glen, PA 19002; USA
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
